Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Neil and Tra1
Thanks for taking the time to explain neilin62
you can follow them on investegate, or the company website:
https://www.investegate.co.uk/Index.aspx?searchtype=2&words=Bould+Opportunities
McFish2020
Look at Bould Opportunities website, under "investors" section, then publications/circulars
We will relist as CIZ
Neil
nightye1
i believe the 80% discount is the way that a company is valued. As Allan says, the external companies used a number of models to determine the value. One of the usual models is "discounted cash flow". This is where a value is determined by projection of future cash revenue, but then discounted as it is based on future value, not today's actual value. (as we haven't achieved those revenues yet) In our case, we are also seen as an early stage company, so the discount levied has been determined as 80%. You could look at it another way and see it as a big potential uplift in the share price.
Couple of further things i have gleaned from the information out there.....
The BOD are already in discussions with manufacturers for the reagents.
There is keen interest from institutional investors, which supports the thought that i made previously as to us coming off AIM and listing on main market. Watch this space in the future.
Allan has been talking to high level the Chinese Minister for Health.
We don't have to wait for CE mark /FDA approval to license the technology to other companies., and i expect to see licensing deals being confirmed very shortly with licensing partners, manufacturers and development partners.
I would also take a bet that we will shortly find that we have re-entered into an agreement with a certain Chinese CRO.
SO, friday's share price will be interesting, but the long term is going to be something else!
I said before time is the key factor here, and, IN MY OPINION ONLY, so do your own research,
For those that invested in a certain company i mentioned a few months back, CONGRATULATIONS. If you haven't already seen it, read the RNS issued tonight after trading hours. It just shows that when it all looks lost, dreams can come true.
Neil
Where can I read updates on new as last RNS on here is date October 2019?
Will the relist happen under the ticker BOU?
Been following the forum but just can't seem to see what I'm looking for!
Haha good point and one I haven’t thought about. There will be a footnote somewhere stating the 80% discount is based on something we haven’t been told about
Can anyone answer me, if ciz had 2 separate valuations both at around 21 million.. how it is allan thinks the company is or will be trading at an 80% discount to its competitors? Surely the people valuing the company would have looked at competing companies in the space to achieve a fair value..
Tomorrow AGM and Friday big fireworks! Bargain price 80% discount so few grounds waiting ;-) hopefully HL will allow me to buy at 8am...
I think it is a great company in principle, I'm just not expecting fireworks on day one.
I'm hoping a couple of things pay off so I can help the majority of my cash in BOU.
Got to pay HRMC a tasty £28k by 1st of Aug, half way there. Just need COPL and MTFB now to relist
rooblertwo
No one is suggesting a huge listing, but come on guy at least try and be more positive, you never know you may like it.
Aspen
Just don't get your hopes up for a huge listing.
The market cap is so small it will be under the radar for a while.
Now, those 3rd parties Big and Small that, were avoided by the lack of communication over the past 2 years.
When they learn of Cizzle Biotechnology on the London Stock Exchange following this RTO, what could be their response to our seemingly revolutionary, patented and very efficient immuniassay test for CIZ1 B biomarker?
Only a small holding will not be selling hoping to add more, after been waiting for many months is now sounding very positive for all.
Regardless of Friday's outcome, for me Allan has pulled of a fine job here. I believe, what we now know about Cizzle (already getting used to this name) hints at massive potential.
In the webinar, towards the QnA Allan speaks about the reason for the lack of communication was to avoid third parties getting involved.
Wideglide, I was hoping another holding would break even before Fri, so I can sell and smash the buy button on Cizzle at 8:00am on Friday.
Friday can hurry up.
Thanks, Neil . Don't own many shares but always a bonus getting back what you lost!
I too am looking forward to 8.00AM Friday. I also remember there was a meeting in the UK, whereby AG attended via video link from Japan, he merely could have been on holiday, or this may have been a business trip, now we know there may be a China link up possibly.
Aspen
I am becoming quietly confident, and excited for Friday launch. Popcorn ready. HODL
EXCEPT Cizzle Biotech, there is no single biomarker test for a lung cancer in the world!! That's a heavy statement!
Why they mentioned huge demand in China market? definitely something afoot.
Many thanks I get that part and understand the shares are only worth what some one is willing to pay
it's very simple - for every 500 shares you held in Bou, you will hold 1 in Cizzle. Any balance can be ignored. That gives you your holding. Forget anything about the price, the price that will THEN matter to you is the price they trade at - especially the price when you want to sell. I suggest you keep it that simple.
Good evening all
I have found this process very confusing could anyone clear up these points have new shares have been sold at an 80%
Discount at 10 p and how many.
also does this mean that the board value all shares at 18 pence in that case
Hope some one can help
Well i guess this is Allan Syms reason for talking to China.
Extracts taken from Hindawi BioMed Research International
[1]. Lung cancer is not only the most common cancer in the world, but also the primary reason for death due to cancer [1]. At present, the number of Chinese patients who were newly diagnosed with lung cancer is about 500 thousand each year, and the number is expected to reach one million by 2025
[3]. Currently, the most often used treatments for NSCLC are surgery, radiotherapy, and chemotherapy, in which the complete surgical resection is the most effective method [4]. Despite the improvements of surgical techniques and instruments in recent years, the overall 5-year survival rate for NSCLC patients after surgery is from 15% to 45% [6]. On the other hand, most patients that were diagnosed with NSCLC were already in the unresectable stage of IIIB or IV and the option of surgery treatment was not feasible, which is the main reason why the overall 5-year survival rate of NSCLC patients is only 12%. However, the overall 5-year survival rate can be increased to 50% if patients can be diagnosed in an early stage
[6]. Currently, the diagnosis of NSCLC mainly depends on X-ray, CT, sputum cytology, fiber bronchoscopy, and cellular pathology. However, X-ray is not sensitive to small lesions and covert lesions; sputum cytology only works on lung cancer originated in the center of airways and has a low detection rate; fiber bronchoscopy is not suitable for early diagnosis due to its invasiveness; cellular pathology cannot precisely determine malignance stages [7]. As such, identifying molecular biomarkers for early diagnosis of NSCLC is urgently needed.
Literature review of the top predicted gene biomarkers suggested that most of them were already considered critical for development of NSCLC.
CIZZLE has the technology to help lung cancer sufferers by increasing the 5 year survival rate by 400% !!!
Neil
Certainly no expert, but hope this helps.
Assuming the resolutions all get passed, (no reason to assume otherwise) you will automatically have the new shares in CIZ ( consolidated 500:1 as per the prospectus.
BOU will not exist after the vote.
Neil
Hi All,
I remember this just going in to suspension and now received a large pack in the mail to read through. Struggled to understand most, but question to the experts, do my suspended shares come back to life or are they lost forever ? Second question, do I get any auto entitlement to the CIZ shares (based on the suspended shares from BOU) ?
Thanks
G